RxDoctor Payments Data

John Pearson, MD

Urology · South Hill, VANPI 1497731343

Payments from drug & device makers

$1,949in general payments, 2019–2025

Across 102 payments — averaging $19.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$518
  • Astellas Pharma US Inc$328
  • Johnson & Johnson$218
  • Amgen$138
  • Boston Scientific$107
  • Bayer$107
  • plus $532 from 11 others

What the payments were for

  • Food & beverage$1,949100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,949 in reported general payments places this provider in the 40th percentile of 300 urology providers in Virginia.

See all urology providers in Virginia

Medicare billing

Part B allowed, 2024
$144,336
Medicare patients
487
Services billed
1,401

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron225$185,442
Tamsulosin Hcl932$14,114
Mirabegron ErMirabegron15$9,909
Fesoterodine Fumarate ErFesoterodine Fumarate71$6,623
Finasteride177$2,107
Solifenacin Succinate67$1,655
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst118$1,312
Tolterodine Tartrate ErTolterodine Tartrate15$1,181
Potassium Citrate ErPotassium Citrate12$494
Testosterone Cypionate13$467
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim60$398
Oxybutynin Chloride11$344
Bethanechol Chloride15$300
NitrofurantoinNitrofurantoin Macrocrystal11$181
Ciprofloxacin Hcl94$149

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$328$185,442225 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 300 urology providers in Virginia.

Other urology in South Hill

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →